GlassScriptPhysician profile
Paula A Dithomas
NPI 1740623453
$1,452.04
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,452.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.62 | 2021 | |
| Incyte Corporation | $156.09 | 2021 | |
| Pfizer INC. | $149.77 | 2021 | |
| Celgene Corporation | $123.45 | 2021 | |
| Eisai INC. | $107.30 | 2021 | |
| Janssen Biotech, INC. | $97.62 | 2021 | |
| Seagen INC. | $74.48 | 2021 | |
| Lilly USA, LLC | $57.06 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $55.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $52.89 | 2021 | |
| Morphosys, US INC. | $45.77 | 2021 | |
| Emd Serono, INC. | $36.32 | 2021 | |
| Merck Sharp & Dohme LLC | $31.63 | 2021 | |
| Amgen INC. | $26.15 | 2021 | |
| Exelixis INC. | $24.53 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $23.54 | 2021 | |
| Daiichi Sankyo INC. | $23.53 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.42 | 2021 | |
| Beigene USA, INC. | $20.49 | 2021 | |
| Servier Pharmaceuticals LLC | $20.15 | 2021 | |
| Glaxosmithkline, LLC. | $19.88 | 2021 | |
| Dova Pharmaceuticals | $19.67 | 2021 | |
| Kite Pharma, INC. | $18.65 | 2021 | |
| Karyopharm Therapeutics INC. | $18.63 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.40 | 2021 | |
| Myovant Sciences INC. | $14.63 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Dithomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.